# Comprehensive Evaluation of the Potential Liver Donor: Review of Process and Best Practices

Jaime Cisek RN, BSN University of Colorado Hospital UCHealth, Aurora CO



#### Disclosures

- No financial disclosures
- This talk was developed with the help of my amazing transplant team





# How many of you are either starting a liver program or are new to role?



### **Objectives**

- 1. Review background of live donor liver transplant (LDLT)
- 2. Benefits of LDLT
- 3. Review components of a living donor evaluation
- 4. Get as excited about living liver donation as I am




## Background

- Introduced to address the shortage of organs available with deceased donor transplant
- Began with pediatric LDLT
- Almost 9,000 of live donor liver transplants have been performed nationwide
- Growing in popularity but only accounts for approximately 5% of transplants performed yearly

Approximately 50 large and small programs in the country



OPTN. SRTR. 2022



#### 14th Annual Living Donation Conference

Presented by the American Foundation for Donation and Transplantation

Lentine et al. Clinical Transplantation. 2023.

#### **Benefits to LDLT**

- Offers candidates excellent long-term outcomes
- Transplanted faster
- Those not represented by MELD have access to transplant
- Lower rates of recipient mortality compared to staying on the waitlist
- Optimize recipient for the time of transplant
- Allows for transplantation before additional decompensations occur



# Can LDLT Ever Be Pursued with Acceptable Risk to the Donor?

#### The Vancouver Forum: established practice principles for LDLT

- LDLT should only be performed if the risk to the donor is justified by the expectation of an acceptable outcome in the recipient.
- Indications for LDLT should be the same as those established for DDLT
- LDLT should offer an overall advantage to the recipient when compared to waiting



#### 14th Annual Living Donation Conference

Presented by the American Foundation for Donation and Transplantation

Pruett et al. The Vancouver Forum. Transplantation. 2006. Barr ML et al. The Vancouver Forum. Transplantation. 2006.

### **Double Equipoise**

- Described by the balance between the recipient's survival benefit and the probability of mortality for the donor
- Balance the risk of the donor to the benefit of the recipient
- Careful selection through a thorough donor evaluation





14th Annual Living Donation Conference

Presented by the American Foundation for Donation and Transplantation

Pruett et al. The Vancouver Forum. Transplantation. 2006. Barr ML et al. The Vancouver Forum. Transplantation. 2006.

#### **Ethical Principles**





- Medical evaluation should:
  - Assess general health of the donor
  - Assess compatibility of the donor to the recipient
  - Screen donor for conditions that increase donor's surgical risk
  - Perform tests to identify potential for transmission of diseases

There is a lack of standardization in this country. Recent survey conducted by University of Colorado team, led by Dr. Whitney Jackson, to evaluate the practice patterns of all active live donor liver transplant programs in the country



**14th Annual Living Donation Conference** Presented by the American Foundation for Donation and Transplantation

HRSA. OPTN. 2006

#### **Components to Consider**

#### What should be the age cut-off?

- Lower age of 18 due to concerns surrounding maturity and ability to give informed consent
- 75% of centers use upper age limit of 55-60





#### 14th Annual Living Donation Conference

Presented by the American Foundation for Donation and Transplantation

Jackson et al. Liver Transplantation. 2022. Gazala et all. Annual Review of Medicine. 2019

#### When should a liver biopsy be performed?


- Most centers have a protocol for performing pre donation biopsy
  - Steatosis on imaging (10% often a trigger)
    - Steatosis assessment
    - How much is too much?
  - Elevated LFTs
  - BMI threshold
  - Metabolic risk factors
  - Other indications for biopsy



14th Annual Living Donation Conference

Presented by the American Foundation for Donation and Transplantation

#### **Other Indications for a Liver Biopsy**



Presented by the American Foundation for Donation and Transplantation

Founda

Jackson et al. Liver Transplantation. 2022.

#### Our Center Experience

		Indications (N=92)	
	BMI ≥ 28 kg/m²	30	
_	Positive ANA	20	
000	1° Relative with AILD	14	
Protocol	A1AT Heterozygote	9	
-	Abnormal Liver Enzymes	5	
	Steatosis on Imaging	8	
	Abnormal Imaging	2	
	HBcAb	2	
Misc.	HFE Heterozygote	1	
	Low ceruloplasmin + Abnormal 24 hour urine	1	

Indication	Frequency of Rule Out	Pathological Finding	
BMI	2/21 (9.5%)	Non-specific hepatitis	
DIVII		Drug induced injury	
BMI with Steatosis	1/5 (20%)	Steatohepatitis	
BMI with 个 LFTs 2/2 (100%)		Steatohepatitis	
	3/20 (15%)	Thick walled hepatic arterioles	
ANA		Non-specific portal inflammation/periportal hemosiderosis	
		Minimally active lobular hepatitis	
↑ LFTs (normal	2/3 (66%)	Steatohepatitis	
BMI)		Mild acute hepatitis w/focal lymphocytic cholangitis	
Steatosis on imaging (normal BMI)	1/3 (33%)	Steatosis (20%)	




14th Annual Living Donation Conference

Presented by the American Foundation for Donation and Transplantation

Cisek et al. ATC. 2021.

#### Should we screen for venous thromboembolism (VTE)?

Large programs report having protocols for VTE



Most Frequently Used

Presented by the American Foundation for Donation and Transplantation

Jackson et al. Liver Transplantation. 2022.


#### How should we assess cardiovascular status?

- Almost all centers have a protocol to evaluate cardiovascular disease risk (CVD)
- Based on risk factors
- 1. Ischemic Evaluation
  - Stress test
  - Cardiac computed tomography (CT) angiogram
- 2. Structural assessment
  - TTE
- 3. Cardiology Consult



#### What should be the maximum allowable BMI?

- 92% of centers had a max BMI
- Median BMI 32
- Why is there a max?



**Donor BMI Threshold** 



#### 14th Annual Living Donation Conference

Presented by the American Foundation for Donation and Transplantation

Jackson et al. Liver Transplantation. 2022.

#### What else should we screen for?

- Autoimmune Markers
  - Most centers routinely assess for autoimmune diseases
    - ANA
    - AMA
    - SMA
- Hereditary Markers
  - Alpha-1-antitrypsin
  - Hereditary hemochromatosis
  - Wilson's disease



- Transmissible Diseases
  - CMV
  - HIV
  - Hepatitis B
  - Hepatitis C
  - Syphilis
- Endemic Risk
  - Unique to your region



# **Surgical Evaluation**


- Surgical history
  - History of abdominal surgeries
- Imaging studies
  - CT scan
    - Liver volumes
    - Blood vessel anatomy
  - MRCP
    - Biliary Anatomy
  - 3D Imaging
  - Mevis

n Found.



Presented by the American Foundation for Donation and Transplantation

#### Anatomical Considerations in Selecting the Donor-Recipient Pair



# **Surgical Evaluation**

- Graft weight-Body Weight Ratio (GWBWR)
  - 0.8% graft minimum
  - 1.0% ideal
  - Example: 80kg recip. We want an 800g right lobe.
- Other factors to consider for graft size:
  - How sick is the recipient (portal hypertension)?
  - Does the graft contain fat?
- Minimize risk for donor. Maximize benefit for recipient


 Size is always a balance between donor risk and recipient need

> 14th Annual Living Donation Conference Presented by the American Foundation for Donation and Transplantation


Kiuchi T et al. Transplantation. 1999. Ben-Haim et al. Liver Transplantation. 2001.

# **The Surgery**

nd Team



Presented by the American Foundation for Donation and Transplantation



**14th Annual Living Donation Conference** Presented by the American Foundation for Donation and Transplantation

Id Traff

# **Mortality and Morbidity**

#### The debate revolves around how much risk is acceptable for a donor

#### Mortality

- A2ALL data (through 2013) reported donor mortality rate of 1 in 200
- SRTR report summarizes 2016-2020
  - Total number of LDLTs: 2128
- Major centers in US broadly quoting mortality risk =/< 1 in 500</li>

Cause	0-30 days	31-90 days	91-365 days
Suicide	0	0	0
Accident/homicide	0	0	0
Medical	1	0	0
Cancer	0	0	0
Unknown	0	0	0
TOTAL	1	0	0

#### 14th Annual Living Donation Conference

Presented by the American Foundation for Donation and Transplantation

A2ALL. 2013 OPTN. SRTR. 2020

# **Mortality and Morbidity**

#### Morbidity

- Approximately 30 40% of donors will experience an early complication
- Only 10-15% of those complications will require considerable intervention
- Major vs. Minor complications



14th Annual Living Donation Conference

Presented by the American Foundation for Donation and Transplantation

Ladner DP et al. J Hepatol. 2015 Olthoff KM et al. Liver Transplanatation. 2015 Trotter JF et al. Transplantation. 2007. Sotiropoulos GC et al. Annals of Surgery. 2011

- Evaluation by a psychiatrist or psychologist
- Review psychological issues that may complicate a donor's recovery
- Attempt to identify factors that warrant educational or theurapeutic intervention prior to donation
- Determine ability to make informed decision



14th Annual Living Donation Conference Presented by the American Foundation for Donation and Transplantation

Guidance for the Medical Evaluation of Potential Living Liver Donors-OPTN. 2013.

- Psychological testing
  - Provides objective data
  - 1. Personality Assessment Inventory (PAI)
    - Screens for psychopathology
    - Measures somatic concerns
  - 2. Millon Behavioral Health Diagnostic
    - Focuses on coping strategies and orientation to health
    - Used in kidney donors

#### Interview with donor and provider to determine risk



#### Case Study

- 25 year old female, works as an ICU RN at a local hospital
- Reports history of anxiety
- Medications included bupropion 75mg daily
- Given PAI testing
- Anxiety-related disorders scale above level of significance (LOS)
- Obsessive-compulsive subscale also above LOS



- Psychologist reported she described a number of experiences consistent with and suggestive of obsessive compulsive disorder (OCD)
- She was referred for local psychiatric consultation and exposure therapy
- Recommended she start SSRI therapy with 6 weeks of treatment before proceeding with donation
- Received consult service during the index hospitalization for donation
- Donor reported at all subsequent follow ups that she felt those early interventions was the reason for a successful post donation course.
- Has continued her therapy and has a "much clearer sense of her OCD symptoms" and has been able to manage her compulsions.



### **Social Evaluation**

- Eval usually performed by a licensed clinical social worker (LCSW)
- Special emphasis on:
  - Employment
  - Health insurance status
  - Living arrangements
  - Social instability
  - Motivation for donation
  - Coping strategies



14th Annual Living Donation Conference

Presented by the American Foundation for Donation and Transplantation

Guidance for the Medical Evaluation of Potential Living Liver Donors-OPTN. 2013.

# Independent Living Donor Advocate

- Functions Independently from the recipient's transplant team
- · Can be physician, chaplain, often times a social worker
- Explains and supports the rights as a donor
- Assure the donor is willing to donate without feeling pressure
- Assess that the donor understands the components of informed consent
- Remind the donor they can decide not to donate at any time



14th Annual Living Donation Conference Presented by the American Foundation for Donation and Transplantation

American Society of Transplantation


### Summary

- We know there is a shortage of deceased organs in this country. While living donation is increasing, it still only represents a small percentage of transplants performed every year.
- LDLT offers excellent outcomes for recipients while demonstrating justifiable risk to the donor.
- Evaluation of a potential living donor must be a careful consideration from the multi-disciplinary team.



#### Conclusion

Living donation helps thousands of recipients get transplanted every year that could otherwise die on the liver transplant list. Through thoughtful and thorough evaluation, we can safely perform these living donor surgeries with outstanding outcomes for both the donor and recipient.



Dr Hillary Yaffe

Lindsay Pratt, PAC I SHARED A SLIVER

JU

OF MY LIVER

GOT A SLIVER

Parents

Jeremy and Joel

LIVER TRANSPLANT

to my heart noods a LIVER TRANSPLANT

Claire and Peri

HP.

LIVE

IVER

#### **Session Survey**

#### Jaime Cisek, RN, BSN | April 19th 2:00 PM-2:45 PM





14th Annual Living Donation Conference

Presented by the American Foundation for Donation and Transplantation